Which long‑term antidepressants are associated with tremor as an adverse effect?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Which Long-Term Antidepressants Cause Tremor?

Tremor is a well-recognized adverse effect of multiple antidepressant classes, with SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), and tricyclic antidepressants (TCAs) being the most common culprits in long-term use.

Primary Offending Antidepressants

The most frequently implicated antidepressants causing tremor include:

  • SSRIs and SNRIs: These are among the most common tremor-inducing antidepressants 1, 2. Recent data from Pakistan showed tremor as a significant adverse effect, with TCAs demonstrating increased odds of tremor (OR 2.66,95% CI 1.22-5.94, p = 0.015) 3.

  • Tricyclic antidepressants (TCAs): These older agents carry substantial risk for tremor and other movement disorders 4, 2.

  • Other classes: Atypical antidepressants, mood stabilizers like lithium and valproate, and MAOIs can all induce tremor, though through different mechanisms 1, 5, 6.

Clinical Characteristics of Antidepressant-Induced Tremor

The tremor typically resembles essential tremor or parkinsonian tremor depending on the specific drug mechanism 1. Key features to assess:

  • Onset timing: Median onset is 45 days after initiation, though this varies by drug class (MAOIs show the longest median onset at 91 days) 7
  • Tremor type: Usually postural or action tremor with SSRIs/SNRIs; may be rest tremor with dopamine-blocking agents
  • Associated features: Look for other movement disorders (akathisia, dystonia, dyskinesia) that commonly co-occur 4

Risk Factors to Identify

Patients at higher risk include:

  • Polypharmacy
  • Male gender
  • Older age
  • High doses or immediate-release formulations
  • Toxic drug levels 1

Management Algorithm

1. Confirm drug causation: Review medication timeline, dose escalations, and temporal relationship to tremor onset.

2. Immediate action - Adjust or discontinue the offending agent 4, 2:

  • If tremor is mild and depression control is excellent: Consider dose reduction
  • If tremor is moderate-to-severe or functionally limiting: Switch to an alternative antidepressant with lower tremor risk
  • Bupropion is the preferred alternative as it has demonstrated lower rates of neurological adverse effects compared to SSRIs 8

3. Monitor for resolution: Most drug-induced tremors resolve after discontinuation, though tardive tremor (persistent tremor after prolonged exposure) can occur 1, 6.

4. If tremor persists beyond 3-6 months after drug discontinuation: Consider dopamine transporter (DAT) imaging to evaluate for underlying nigrostriatal degeneration, as the drug may have unmasked an underlying movement disorder 6.

Critical Pitfalls to Avoid

  • Do not assume tremor is benign essential tremor without reviewing the medication list - this delays appropriate intervention 2
  • Do not add symptomatic tremor treatment (beta-blockers, primidone) without first addressing the causative drug - this adds unnecessary polypharmacy 1
  • Watch for serotonin syndrome, which presents with tremor plus other features (hyperthermia, altered mental status, hyperreflexia) - this is a medical emergency requiring immediate drug cessation 7
  • Recognize that combination therapy increases risk - mirtazapine combinations showed higher rates of metabolic and neurological effects 3

Evidence Quality Note

While the American College of Physicians guidelines 8 comprehensively address antidepressant adverse effects, they provide limited specific detail on tremor. The most commonly reported adverse events in these guidelines were constipation, diarrhea, dizziness, headache, insomnia, nausea, sexual dysfunction, and somnolence, with tremor not prominently featured in the primary analysis. However, recent specialized literature on drug-induced movement disorders 1, 2, 6, 7 provides robust evidence that tremor is a clinically significant and underrecognized complication of long-term antidepressant therapy.

The bottom line: When tremor develops on long-term antidepressant therapy, the priority is to identify and discontinue or switch the offending agent rather than add symptomatic treatment, as this directly addresses both the tremor and avoids unnecessary medication burden.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.